EUVIMEDEUVIMED felfedezése
Crossref

Single‐Center Outcomes of Conversion to Belatacept in Kidney Transplant Recipients

Eve Carciofi iD, Spencer LeCorchick iD, Lance Lindberg iD, Rebecca Braun iD, Elise Heiman, Li Dong iD, Zubair Zafar iD, Sanjiv Anand iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70220 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Eve Carciofi and 7 co-authors. Institution: Department of Pharmacy, Intermountain Medical Center, Murray, Utah, USA. Major MEDLINE topics: Kidney Transplantation, Graft Rejection, Abatacept, Immunosuppressive Agents. Cited 1 times so far (Crossref); 21 references.

AbsztraktSubjectsBibliográfiai adatokCiteRelated studies

Abstract (original language)

Belatacept (Bt) conversion is associated with increased rejection risk in kidney transplant patients (KTxP). The study included patients who underwent kidney transplant and were converted to Bt. Induction was given, followed by maintenance with a calcineurin inhibitor (CNI), antimetabolite, and steroid. CNI was tapered post‐Bt based on patient risk. Patients were divided into three cohorts: rejection prior to conversion (RP), no rejection (NR), and rejection after conversion (RA). The primary outcome was biopsy‐proven acute rejection (BPAR) at 1 year post conversion. Secondary outcomes included change in estimated glomerular filtration rate (eGFR) and 12‐month patient and graft survival. Concordance with dd‐cfDNA, MMDx, and eplet matching was analyzed for each BPAR incidence. Out of 69 patients included in the study, 10.1% had BPAR post conversion. RP patients’ eGFR was lower at 12 months post conversion, median 23 mL/min (IQR 16–45) compared to NR and RA patients, 44 mL/min (31–66) and 39 mL/min (34–50) respectively. Dd‐cfDNA was elevated prior to biopsy in all RA biopsies. Histopathologic findings differed from MMDx reports 75% of the time. Rejection prior to Bt conversion is associated with lower eGFR, whereas rejection after Bt conversion maintains an eFGR similar to those without rejection. Bt conversion should be considered safe and effective.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationGraft RejectionAbataceptImmunosuppressive AgentsKidney Failure, ChronicPostoperative ComplicationsHumansMaleFemaleGraft SurvivalMiddle AgedGlomerular Filtration RateFollow-Up StudiesPrognosisRisk FactorsKidney Function TestsRetrospective StudiesAdultTransplant Recipients

Author keywords

belataceptdonor‐derived cell‐free DNAepletkidney transplantmolecular microscope

Substances

AbataceptImmunosuppressive Agents

Authors and institutions

  • Department of Pharmacy, Intermountain Medical Center, Murray, Utah, USA.
  • Enterprise Analytics, Intermountain Medical Center, Murray, Utah, USA.
  • Nephrology Associates of Utah, Salt Lake City, Utah, USA.

ORCID profiles: Eve Carciofi, Spencer LeCorchick, Lance Lindberg, Rebecca Braun, Li Dong, Zubair Zafar, Sanjiv Anand

Cite

APA

Carciofi, E., LeCorchick, S., Lindberg, L., Braun, R., Heiman, E., Dong, L., Zafar, Z., & Anand, S. (2025). Single‐Center Outcomes of Conversion to Belatacept in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70220

Vancouver

Carciofi E, LeCorchick S, Lindberg L, Braun R, Heiman E, Dong L, et al. Single‐Center Outcomes of Conversion to Belatacept in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70220

BibTeX
@article{Carciofi2025,
  author = {Carciofi, Eve and LeCorchick, Spencer and Lindberg, Lance and Braun, Rebecca and Heiman, Elise and Dong, Li and Zafar, Zubair and Anand, Sanjiv},
  title = {Single‐Center Outcomes of Conversion to Belatacept in Kidney Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70220}
}
Start for free →